Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences, Inc. ("Spruce Biosciences") (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with ...

Spruce Biosciences prices $60M public offering at $50.00 per share

Spruce Biosciences (SPRB) has priced its public offering of 1.15M common stock shares at $50.00 each.  It is also offering pre-funded warrants to a specific investor for 50K shares at $49.99 each. The ...

Why is Spruce Biosciences stock sinking Tuesday?

Spruce Biosciences, Inc. SPRB shares fell in Tuesday premarket trading after the company priced a public offering of common ...
Yahoo Finance

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET "This ...
FierceBiotech

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

Spruce Biosciences has swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for a speedy approval ...